secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monogram Technologies Inc. (—)
CIK:        0001769759
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001104659-24-060937
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monogram Orthopaedics Q1 net loss $3.5M; 510(k) submission on track for H2 2024
-------------------------------------------------------------------------------

- Net loss $3.5M in Q1 2024 vs $3.9M prior year; cash $10.1M at Mar 31.
- Verification & validation testing expected largely complete in Q2 2024.
- FDA 510(k) submission for mBôs TKA system planned for second half of 2024.
- Engaged contract research organization for OUS clinical trial activities.
- R&D expenses $2.4M, up from $1.9M, driven by V&V and mVision development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1769759/000110465924060937/0001104659-24-060937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1769759/000110465924060937/tm2414401d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer